A new treatment regimen that includes a Bruton’s tyrosine kinase inhibitor was approved for follicular lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zanubrutinib (Brukinsa) in combination with obinutuzumab...
First-line nivolumab with chemotherapy was approved for bladder cancer. The U.S. Food and Drug Administration (FDA) has approved nivolumab (Opdivo) in combination with cisplatin and gemcitabine for the first-line treatment of patients with unresectable...
The FDA has approved inotuzumab ozogamicin for pediatric patients with certain leukemias. The U.S. Food and Drug Administration (FDA) has approved inotuzumab ozogamicin (Besponsa) for the treatment of pediatric patients aged 1 year or...
The FDA has approved amivantamab-vmjw, both alone and in combination with chemotherapy, for the treatment of certain non-small cell lung cancers. The U.S. Food and Drug Administration (FDA) has approved amivantamab-vmjw (Rybrevant), in combination...
The FDA has approved osimertinib plus chemotherapy for non-small cell lung cancer with EGFR mutations. The U.S. Food and Drug Administration (FDA) has approved osimertinib (Tagrisso) plus platinum-based chemotherapy for the treatment of patients...
The FDA has granted accelerated approval to lifileucel, a new type of cell therapy, for the treatment of melanoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to lifileucel (Amtagvi) for...
The FDA has granted full approval to tepotinib for some non-small cell lung cancers that harbor a certain mutation in the MET gene. The U.S. Food and Drug Administration (FDA) has approved tepotinib (Tepmetko)...
The FDA has approved irinotecan liposome plus chemotherapy for the first-line treatment of metastatic pancreatic cancer. The U.S. Food and Drug Administration (FDA) has approved irinotecan liposome (Onivyde), in combination with the chemotherapeutics oxaliplatin,...
The FDA has approved the FGFR inhibitor erdafitinib for certain patients with urothelial carcinoma The U.S. Food and Drug Administration (FDA) has approved erdafitinib (Balversa) for the treatment of adult patients with locally advanced...
The FDA expanded the indications for pembrolizumab to include more patients with stage III-IVA cervical cancer. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) plus chemoradiotherapy (CRT) for the treatment of...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now